Under the guidance of UGT1A1 genotype, some researchers explored the efficacy and safety of the regimen of regorafenib combined with increased-dose FOLFIRI for metastatic colorectal cancer patients[43]. Here, UGT1A1 is linked to metastatic colorectal cancer.